查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1602791

發炎治療市場：按藥物類別、適應症和用途分類 - 2025-2030 年全球預測

Anti-Inflammatory Therapeutics Market by Drug Class (Anti-inflammatory Biologics, Corticosteroids, Non-steroidal Anti-inflammatory Drugs ), Indication, Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年發炎治療市值為1,015.3億美元，預計到2024年將達到1,038.5億美元，複合年成長率為4.93%，到2030年將達到1,422.1億美元。

發炎治療市場包括減少發炎是關節炎、氣喘和發炎性腸道疾病腸道疾病等許多疾病的通用途徑。人口老化、慢性病盛行率上升以及人們對早期療育發炎疾病益處的認知不斷提高，推動了需求的激增。發炎治療對於現代醫學至關重要，其在藥物、生技藥品和生物相似藥中的應用，最終用戶範圍從醫院、診所到研究機構。該市場的成長受到生物技術進步、新治療方法的採用以及全球醫療基礎設施投資增加的顯著影響。個人化醫療和標靶治療帶來了有望提高療效和減少副作用的新機會。在關鍵地區有利的法律規範和快速的醫藥品認證過程的支持下，生物製藥產業仍然是創新和研究的沃土。儘管存在這些機遇，但市場仍面臨高昂的研發成本、嚴格的監管要求以及潛在的副作用等挑戰，阻礙了市場進入和開拓。此外，來自學名藥和替代藥物的競爭威脅著市場的擴張。為了實現永續的業務成長，公司應專注於基於人工智慧的藥物發現和生物相似藥開發等創新方法。此外，建立策略聯盟和投資新興國家可以提供競爭優勢。市場的本質是動態的，受到科學進步和不斷增加的以患者為中心的方法的推動。因此，公司需要保持敏捷並密切監控監管變化和技術進步，以捕捉潛在的市場變化。認知到整體、有針對性的治療的重要性並促進跨部門合作對於抓住發炎治療市場的未來成長機會至關重要。

主要市場統計
基準年[2023] 1015.3億美元
預測年份 [2024] 1038.5億美元
預測年份 [2030] 1422.1億美元
複合年成長率（%） 4.93%

市場動態：揭示快速發展的發炎治療市場的關鍵市場洞察

供需的動態交互作用正在改變發炎治療市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 全球慢性病盛行率
    • 增加治療發炎疾病的生技藥品的可用性
    • 政府不斷採取措施提高人們對發炎治療的認知
  • 市場限制因素
    • 與發炎治療相關的高成本
  • 市場機會
    • 活性化發炎治療的研發
    • 發炎治療的核准流程不斷增加
  • 市場問題
    • 與發炎治療相關的某些副作用

波特五力：開拓發炎治療市場的策略工具

波特的五力框架是了解發炎治療市場競爭格局的關鍵工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解發炎治療市場的外部影響

外部宏觀環境因素在塑造發炎治療市場的表現動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助企業預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析：了解發炎治療市場的競爭格局

發炎治療市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣：發炎治療市場供應商的績效評估

FPNV定位矩陣是評估發炎治療市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：繪製發炎治療市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，發炎治療市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1. 市場滲透率：詳細檢視當前市場環境，主要企業的廣泛資料，評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球慢性病盛行率高
      • 增加治療發炎疾病的生技藥品的可用性
      • 政府加大力度提高發炎治療意識
    • 抑制因素
      • 與發炎治療相關的高成本
    • 機會
      • 擴大發炎治療的研發活動
      • 發炎治療的核准流程增加
    • 任務
      • 與發炎治療相關的某些副作用
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章發炎治療市場：依藥物類別

  • 介紹
  • 發炎生技藥品
  • 皮質類固醇
  • 非類固醇消炎劑(NSAID)

第7章發炎治療市場：依適應症分類

  • 介紹
  • 抗發發炎性腸道疾病
  • 關節炎
  • 多發性硬化症
  • 乾癬
  • 呼吸系統疾病

第8章發炎治療市場：依應用分類

  • 介紹
  • 自體免疫
  • 發炎疾病
  • 呼吸系統疾病

第9章美洲發炎治療市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太發炎治療市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲發炎治療市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbvie, Inc.
  • Algen Healthcare Ltd.
  • Allegiant Health
  • Alvogen
  • Amgen Inc.
  • Amneal Pharmaceuticals LLC
  • Arcutis BIoTherapeutics, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Clearsynth Labs Limited
  • Genentech, Inc. by Roche Group
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Kymera Therapeutics
  • Novartis AG
  • Pfizer Inc.
  • Pharbest Pharmaceuticals, Inc.
  • Sanofi Group
  • Spectrum Chemical Mfg. Corp.
  • Sun Pharmaceutical Industries Ltd.
  • Teikoku Seiyaku Co., Ltd.
Product Code: MRR-5C6F41F5B03B

The Anti-Inflammatory Therapeutics Market was valued at USD 101.53 billion in 2023, expected to reach USD 103.85 billion in 2024, and is projected to grow at a CAGR of 4.93%, to USD 142.21 billion by 2030.

The anti-inflammatory therapeutics market encompasses treatments designed to alleviate inflammation, a common pathway in numerous diseases, including arthritis, asthma, and inflammatory bowel diseases. The burgeoning demand is fueled by an aging population, increasing prevalence of chronic diseases, and heightened awareness of the benefits of early intervention in inflammatory conditions. Anti-inflammatory therapeutics are essential in modern medicine, offering applications in pharmaceuticals, biologics, and biosimilars, with end-users ranging from hospitals and clinics to research institutes. Growth in this market is significantly influenced by advancements in biotechnology, the introduction of novel therapeutic methods, and the increasing investment in healthcare infrastructure globally. Personalized medicine and targeted therapies provide an emerging opportunity, promising enhanced efficacy and reduced side effects. The biopharmaceutical sector, supported by favorable regulatory frameworks and expedited drug approval processes in key regions, remains a fertile ground for innovation and research. Despite these opportunities, the market faces challenges such as high R&D costs, strict regulatory requirements, and the potential for adverse drug reactions, which can impede market entry and development. Furthermore, competition from generic drugs and alternative medicine poses a threat to market expansion. For sustainable business growth, companies should focus on innovative approaches like AI-driven drug discovery and the development of biosimilars. Additionally, forming strategic alliances and investing in emerging economies could offer competitive advantages. The nature of the market is dynamic, fueled by scientific advancements and increasing patient-centric approaches. Therefore, businesses should be agile, closely monitoring regulatory changes and technological advancements to seize potential market shifts. Recognizing the importance of holistic, evidence-based treatments, and fostering cross-disciplinary collaborations will be crucial for capturing future growth opportunities in the anti-inflammatory therapeutics market.

KEY MARKET STATISTICS
Base Year [2023] USD 101.53 billion
Estimated Year [2024] USD 103.85 billion
Forecast Year [2030] USD 142.21 billion
CAGR (%) 4.93%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Anti-Inflammatory Therapeutics Market

The Anti-Inflammatory Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • High prevalence of chronic disorders globally
    • Rising availability of biologic drugs for the treatment of inflammatory conditions
    • Growing government initiatives to expand the awareness of inflammatory therapeutics
  • Market Restraints
    • High cost associated with anti-inflammatory therapeutics
  • Market Opportunities
    • Growing research & development activities to develop anti-inflammatory therapeutics
    • Rising approval process for anti-inflammatory therapeutics
  • Market Challenges
    • Certain side effects associated with anti-inflammatory therapeutics

Porter's Five Forces: A Strategic Tool for Navigating the Anti-Inflammatory Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Anti-Inflammatory Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Anti-Inflammatory Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Anti-Inflammatory Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Anti-Inflammatory Therapeutics Market

A detailed market share analysis in the Anti-Inflammatory Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Anti-Inflammatory Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Anti-Inflammatory Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Anti-Inflammatory Therapeutics Market

A strategic analysis of the Anti-Inflammatory Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anti-Inflammatory Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbvie, Inc., Algen Healthcare Ltd., Allegiant Health, Alvogen, Amgen Inc., Amneal Pharmaceuticals LLC, Arcutis Biotherapeutics, Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Clearsynth Labs Limited, Genentech, Inc. by Roche Group, GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Kymera Therapeutics, Novartis AG, Pfizer Inc., Pharbest Pharmaceuticals, Inc., Sanofi Group, Spectrum Chemical Mfg. Corp., Sun Pharmaceutical Industries Ltd., and Teikoku Seiyaku Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Anti-Inflammatory Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Anti-inflammatory Biologics, Corticosteroids, and Non-steroidal Anti-inflammatory Drugs (NSAIDs).
  • Based on Indication, market is studied across Anti-inflammatory Bowel Disease, Arthritis, Multiple Sclerosis, Psoriasis, and Respiratory Disease.
  • Based on Application, market is studied across Autoimmune, Inflammatory Diseases, and Respiratory Diseases.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. High prevalence of chronic disorders globally
      • 5.1.1.2. Rising availability of biologic drugs for the treatment of inflammatory conditions
      • 5.1.1.3. Growing government initiatives to expand the awareness of inflammatory therapeutics
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with anti-inflammatory therapeutics
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing research & development activities to develop anti-inflammatory therapeutics
      • 5.1.3.2. Rising approval process for anti-inflammatory therapeutics
    • 5.1.4. Challenges
      • 5.1.4.1. Certain side effects associated with anti-inflammatory therapeutics
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Anti-Inflammatory Therapeutics Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Anti-inflammatory Biologics
  • 6.3. Corticosteroids
  • 6.4. Non-steroidal Anti-inflammatory Drugs (NSAIDs)

7. Anti-Inflammatory Therapeutics Market, by Indication

  • 7.1. Introduction
  • 7.2. Anti-inflammatory Bowel Disease
  • 7.3. Arthritis
  • 7.4. Multiple Sclerosis
  • 7.5. Psoriasis
  • 7.6. Respiratory Disease

8. Anti-Inflammatory Therapeutics Market, by Application

  • 8.1. Introduction
  • 8.2. Autoimmune
  • 8.3. Inflammatory Diseases
  • 8.4. Respiratory Diseases

9. Americas Anti-Inflammatory Therapeutics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Anti-Inflammatory Therapeutics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Anti-Inflammatory Therapeutics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbvie, Inc.
  • 2. Algen Healthcare Ltd.
  • 3. Allegiant Health
  • 4. Alvogen
  • 5. Amgen Inc.
  • 6. Amneal Pharmaceuticals LLC
  • 7. Arcutis Biotherapeutics, Inc.
  • 8. Astellas Pharma Inc.
  • 9. AstraZeneca PLC
  • 10. Bayer AG
  • 11. Bristol-Myers Squibb Company
  • 12. Clearsynth Labs Limited
  • 13. Genentech, Inc. by Roche Group
  • 14. GlaxoSmithKline PLC
  • 15. Johnson & Johnson Services, Inc.
  • 16. Kymera Therapeutics
  • 17. Novartis AG
  • 18. Pfizer Inc.
  • 19. Pharbest Pharmaceuticals, Inc.
  • 20. Sanofi Group
  • 21. Spectrum Chemical Mfg. Corp.
  • 22. Sun Pharmaceutical Industries Ltd.
  • 23. Teikoku Seiyaku Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. ANTI-INFLAMMATORY THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ANTI-INFLAMMATORY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. ANTI-INFLAMMATORY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTI-INFLAMMATORY THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTI-INFLAMMATORY THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY BOWEL DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PSORIASIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY RESPIRATORY DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. ANTI-INFLAMMATORY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 149. ANTI-INFLAMMATORY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023